Pharma investing in India (Morning Read)

Read current medical news from today, including: pharma investing in India, Pfizer’s Huntington disease study comes to a disappointing end, physician billing could be put online, and the case for open source biology.

Current medical news and unique business news for anyone who cares about the healthcare industry.

Pharma investing in India. There have been more than a dozen deals in India’s pharmaceutical sector since 2009, in part because there are two-fold opportunities for Indian pharma companies.

One is the emerging segment which includes Latin America, South East Asia—here India can offer products and medicines with a better pricing as compared to what it offers in home country. Second is the regulated markets of Japan and US. These markets create opportunity for generics but the trick has to be low pricing by Indian pharma companies.

The case for open source biology. Keep an eye out for Sage Bionetworks Common Congress at the end of this week, a meeting for the supporters of open source biology: “If this thing goes viral throughout biomedicine, it will change the way we think about healthcare. If it doesn’t go viral, it will probably fade into irrelevance.”

Pfizer Huntington disease study ends. Pfizer and Medivation said there was no “statistically significant improvement in patients taking the drug dimebon.” The drug is also being tested for Alzheimer’s disease.

Physician billing data online. New federal legislation would display how much physician receive for treating seniors for items such as x-rays and certain office visits, and such data would be searchable “including on the basis of individual items and services,”